Evidence map›Paper›PMID 36829723›Full record

ReviewBioengineering (Basel, Switzerland)2023

rAAV Manufacturing: The Challenges of Soft Sensing during Upstream Processing.

Cristovão Freitas Iglesias, Milica Ristovski, Miodrag Bolic, Miroslava Cuperlovic-Culf

Abstract readReview
In one paragraph

Review in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cristovão Freitas IglesiasFaculty of Engineering, University of Ottawa, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0002-6448-2083
Milica RistovskiFaculty of Engineering, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Miodrag BolicFaculty of Engineering, University of Ottawa, Ottawa, ON K1N 6N5, Canada.ORCID 0000-0002-8013-8645
Miroslava Cuperlovic-CulfDigital Technologies Research Center, National Research Council, Ottawa, ON K1A 0R6, Canada.ORCID 0000-0002-9483-8159

Funding

National Research Council through AI for Design Challenge Program AI4D-103-1
6 · The paper itself

Abstract

Recombinant adeno-associated virus (rAAV) is the most effective viral vector technology for directly translating the genomic revolution into medicinal therapies. However, the manufacturing of rAAV viral vectors remains challenging in the upstream processing with low rAAV yield in large-scale production and high cost, limiting the generalization of rAAV-based treatments. This situation can be improved by real-time monitoring of critical process parameters (CPP) that affect critical quality attributes (CQA). To achieve this aim, soft sensing combined with predictive modeling is an important strategy that can be used for optimizing the upstream process of rAAV production by monitoring critical process variables in real time. However, the development of soft sensors for rAAV production as a fast and low-cost monitoring approach is not an easy task. This review article describes four challenges and critically discusses the possible solutions that can enable the application of soft sensors for rAAV production monitoring. The challenges from a data scientist's perspective are (i) a predictor variable (soft-sensor inputs) set without AAV viral titer, (ii) multi-step forecasting, (iii) multiple process phases, and (iv) soft-sensor development composed of the mechanistic model.

Indexed as

bioprocess optimizationrAAV productionrecombinant adeno-associated virussoft sensing

Identifiers

PMID36829723
PMCPMC9951952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.